The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Adenocarcinoma


Psychiatry related information on Adenocarcinoma


High impact information on Adenocarcinoma


Chemical compound and disease context of Adenocarcinoma


Biological context of Adenocarcinoma


Anatomical context of Adenocarcinoma


Gene context of Adenocarcinoma

  • Between 4 and 6 months of age, the Smad3 mutant mice become moribund with colorectal adenocarcinomas [29].
  • A number of adenocarcinomas abundantly express and secrete underglycosylated MUC1 mucin [30].
  • These findings in the mouse provide experimental support for the widely accepted model of human pancreatic adenocarcinoma in which activated KRAS serves to initiate PanIN lesions, and the INK4A/ARF tumor suppressors function to constrain the malignant conversion of these PanIN lesions into lethal ductal adenocarcinoma [31].
  • Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma [31].
  • The human WiDr adenocarcinoma line forms solid tumors in immunocompromised mice, and treatment with an anti-LT-beta-R antibody combined with human IFN-gamma arrested tumor growth [32].
  • A fraction of adenocarcinomas lose Dicer as a result of deletions at the Dicer locus [33].
  • Tobacco carcinogens would not be a major factor inducing p16 HDs in lung adenocarcinoma progression [34].
  • The expression of E-cadherin, p-S6, and TTF-1 was evaluated in 77 primary lung adenocarcinomas, in which high p-S6 expression was associated with shorter time to metastasis [35].
  • The number of MRP3-positive cells significantly increased from AAH (the precursor lesion of lung adenocarcinoma) to LNMBAC [36].

Analytical, diagnostic and therapeutic context of Adenocarcinoma


  1. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. Rodenhuis, S., van de Wetering, M.L., Mooi, W.J., Evers, S.G., van Zandwijk, N., Bos, J.L. N. Engl. J. Med. (1987) [Pubmed]
  2. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Maley, C.C., Galipeau, P.C., Finley, J.C., Wongsurawat, V.J., Li, X., Sanchez, C.A., Paulson, T.G., Blount, P.L., Risques, R.A., Rabinovitch, P.S., Reid, B.J. Nat. Genet. (2006) [Pubmed]
  3. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. Virgolini, I., Raderer, M., Kurtaran, A., Angelberger, P., Banyai, S., Yang, Q., Li, S., Banyai, M., Pidlich, J., Niederle, B., Scheithauer, W., Valent, P. N. Engl. J. Med. (1994) [Pubmed]
  4. Hypertension associated with a renin-secreting adenocarcinoma of the pancreas. Ruddy, M.C., Atlas, S.A., Salerno, F.G. N. Engl. J. Med. (1982) [Pubmed]
  5. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., Toyoshima, K. Nature (1986) [Pubmed]
  6. Overexpression of cellular iron import proteins is associated with malignant progression of esophageal adenocarcinoma. Boult, J., Roberts, K., Brookes, M.J., Hughes, S., Bury, J.P., Cross, S.S., Anderson, G.J., Spychal, R., Iqbal, T., Tselepis, C. Clin. Cancer Res. (2008) [Pubmed]
  7. Correlation of natural killer activity with tumorigenesis of a preneoplastic mouse mammary lesion. Wei, W.Z., Fulton, A., Winkelhake, J., Heppner, G. Cancer Res. (1989) [Pubmed]
  8. Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Järvinen, K., Pietarinen-Runtti, P., Linnainmaa, K., Raivio, K.O., Krejsa, C.M., Kavanagh, T., Kinnula, V.L. Am. J. Physiol. Lung Cell Mol. Physiol. (2000) [Pubmed]
  9. Nitrosation of dietary myosmine as risk factor of human cancer. Wilp, J., Zwickenpflug, W., Richter, E. Food Chem. Toxicol. (2002) [Pubmed]
  10. Discoveries of vitamin B12 and selenium enzymes. Stadtman, T.C. Annu. Rev. Biochem. (2002) [Pubmed]
  11. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Zhang, Z., Wang, Y., Vikis, H.G., Johnson, L., Liu, G., Li, J., Anderson, M.W., Sills, R.C., Hong, H.L., Devereux, T.R., Jacks, T., Guan, K.L., You, M. Nat. Genet. (2001) [Pubmed]
  12. Gastroesophageal reflux and adenocarcinoma of the esophagus. Gofman, J.W. N. Engl. J. Med. (1999) [Pubmed]
  13. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. Lagergren, J., Bergström, R., Lindgren, A., Nyrén, O. N. Engl. J. Med. (1999) [Pubmed]
  14. Development of methods for the quantitative in vitro analysis of androgen-dependent and autonomous Shionogi carcinoma 115 cells. Stanley, E.R., Palmer, R.E., Sohn, U. Cell (1977) [Pubmed]
  15. Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. Young, R.C., Chabner, B.A., Hubbard, S.P., Fisher, R.I., Bender, R.A., Anderson, T., Simon, R.M., Canellos, G.P., DeVita, V.T. N. Engl. J. Med. (1978) [Pubmed]
  16. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., Yamamoto, T. Science (1986) [Pubmed]
  17. Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Johnson, E.S., Seely, J.H., White, W.F., DeSombre, E.R. Science (1976) [Pubmed]
  18. Meta-analysis of antioxidant intake and the risk of esophageal and gastric cardia adenocarcinoma. Kubo, A., Corley, D.A. Am. J. Gastroenterol. (2007) [Pubmed]
  19. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo. Watanabe, N., Takaoka, M., Sakurama, K., Tomono, Y., Hatakeyama, S., Ohmori, O., Motoki, T., Shirakawa, Y., Yamatsuji, T., Haisa, M., Matsuoka, J., Beer, D.G., Nagatsuka, H., Tanaka, N., Naomoto, Y. Clin. Cancer Res. (2008) [Pubmed]
  20. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Caldas, C., Hahn, S.A., da Costa, L.T., Redston, M.S., Schutte, M., Seymour, A.B., Weinstein, C.L., Hruban, R.H., Yeo, C.J., Kern, S.E. Nat. Genet. (1994) [Pubmed]
  21. Chromosome 5 allele loss in human colorectal carcinomas. Solomon, E., Voss, R., Hall, V., Bodmer, W.F., Jass, J.R., Jeffreys, A.J., Lucibello, F.C., Patel, I., Rider, S.H. Nature (1987) [Pubmed]
  22. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nelson, W.G., Liu, L.F., Coffey, D.S. Nature (1986) [Pubmed]
  23. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. Jerónimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W.G., Sidransky, D. J. Natl. Cancer Inst. (2001) [Pubmed]
  24. Gastroesophageal reflux and adenocarcinoma of the esophagus. Marshall, K.G. N. Engl. J. Med. (1999) [Pubmed]
  25. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., Varmus, H.E. Genes Dev. (2001) [Pubmed]
  26. Human eosinophils express transforming growth factor alpha. Wong, D.T., Weller, P.F., Galli, S.J., Elovic, A., Rand, T.H., Gallagher, G.T., Chiang, T., Chou, M.Y., Matossian, K., McBride, J. J. Exp. Med. (1990) [Pubmed]
  27. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. Sobol, R.E., Astarita, R.W., Hofeditz, C., Masui, H., Fairshter, R., Royston, I., Mendelsohn, J. J. Natl. Cancer Inst. (1987) [Pubmed]
  28. Lack of Thy 1.2 antigen expression on the surfaces of mouse mammary epithelial cells. Thompson, K. J. Natl. Cancer Inst. (1981) [Pubmed]
  29. Smad3 mutant mice develop metastatic colorectal cancer. Zhu, Y., Richardson, J.A., Parada, L.F., Graff, J.M. Cell (1998) [Pubmed]
  30. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Agrawal, B., Krantz, M.J., Reddish, M.A., Longenecker, B.M. Nat. Med. (1998) [Pubmed]
  31. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., DePinho, R.A. Genes Dev. (2003) [Pubmed]
  32. Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. Browning, J.L., Miatkowski, K., Sizing, I., Griffiths, D., Zafari, M., Benjamin, C.D., Meier, W., Mackay, F. J. Exp. Med. (1996) [Pubmed]
  33. Overexpression of Dicer in precursor lesions of lung adenocarcinoma. Chiosea, S., Jelezcova, E., Chandran, U., Luo, J., Mantha, G., Sobol, R.W., Dacic, S. Cancer Res. (2007) [Pubmed]
  34. Association of p16 homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Iwakawa, R., Kohno, T., Anami, Y., Noguchi, M., Suzuki, K., Matsuno, Y., Mishima, K., Nishikawa, R., Tashiro, F., Yokota, J. Clin. Cancer Res. (2008) [Pubmed]
  35. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. McDonald, J.M., Pelloski, C.E., Ledoux, A., Sun, M., Raso, G., Komaki, R., Wistuba, I.I., Bekele, B.N., Aldape, K. Clin. Cancer Res. (2008) [Pubmed]
  36. Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression. Hanada, S., Maeshima, A., Matsuno, Y., Ohta, T., Ohki, M., Yoshida, T., Hayashi, Y., Yoshizawa, Y., Hirohashi, S., Sakamoto, M. J. Pathol. (2008) [Pubmed]
  37. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. Slebos, R.J., Kibbelaar, R.E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C.J., Wagenaar, S.S., Vanderschueren, R.G., van Zandwijk, N., Mooi, W.J. N. Engl. J. Med. (1990) [Pubmed]
  38. Suppression of lymphoma and epithelial malignancies effected by interferon gamma. Street, S.E., Trapani, J.A., MacGregor, D., Smyth, M.J. J. Exp. Med. (2002) [Pubmed]
  39. Phase II evaluation of carboplatin in advanced endometrial carcinoma. Long, H.J., Pfeifle, D.M., Wieand, H.S., Krook, J.E., Edmonson, J.H., Buckner, J.C. J. Natl. Cancer Inst. (1988) [Pubmed]
  40. Transcriptional control of viral gene therapy by cisplatin. Park, J.O., Lopez, C.A., Gupta, V.K., Brown, C.K., Mauceri, H.J., Darga, T.E., Manan, A., Hellman, S., Posner, M.C., Kufe, D.W., Weichselbaum, R.R. J. Clin. Invest. (2002) [Pubmed]
  41. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. Chen, L., Stacewicz-Sapuntzakis, M., Duncan, C., Sharifi, R., Ghosh, L., van Breemen, R., Ashton, D., Bowen, P.E. J. Natl. Cancer Inst. (2001) [Pubmed]
WikiGenes - Universities